PerkinElmer to Divest Proteomics Business to Concentrate on Human, Environmental Health | GenomeWeb

This story has been updated from an earlier version.

PerkinElmer plans to sell its proteomics product line to focus instead on developing screening and diagnostic tools and technologies for food safety and security applications, the company said last week.

It was not immediately clear whether the company plans to sell off all of its proteomics assets or to retain a portion of them, though PerkinElmer described the entire business line as “discontinued operations” during its fourth-quarter earnings statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.